以下是BioNano 和NYGC开始战略性合作的一则新闻。 NYGC和冷泉港等研究中心是同一级别的，相信这是对IRYS的很大认可，也是向客户宣传的有力工具。
2013年7月8日，BioNano Genomics与纽约基因组研究中心（New York Genome Center Enter, NYGC）正式宣布双方成为战略合作伙伴，同时NYGC购买了一套Irys™系统。
全球商业运营副总裁Todd Dickinson教授说：“纽约基因组中心是北美最大、最雄心勃勃的基因组学和生物信息学机构之一，我们也很高兴他们能把我们的系统平台囊括其中。”“对于BioNano来说是一个重要的里程碑，证明自己有能力提供一个成熟的商业技术，来解决像NYGC这样一个大的研究中心对长片段基因组信息的需求。有了Irys系统提供的最先进长片段读取技术，NYGC可以加快转化研究并最终实现改善人类健康的使命。”
NYGC成立于2010年，通过对基因组数据和资源的整合既加快了生物医学研究速度又提高了临床护理质量。在2012年，NYGC推出全面的基因组解决方案，包含高通量测序，生物信息学分析与数据管理在内的个性化定制服务。今年晚些时候将在曼哈顿设立永久总部，开放其独立的非盈利研究中心的先进设施。该机构将提供给研究人员一个能接触最先进的测序技术和生物信息学的工作环境。
NYGC的科学主管，总裁Robert B. Darnell博士说：“创新和尖端技术是我们给纽约市和外面的研究者提供高质量的基因组测序和生物信息学服务的关键所在。” “基因组学的研究人员和临床医生需要准确全面的基因组结构变异检测，来实现精确的疾病检测与诊断，从而改善全世界患者的疗效。”
基因组测序技术经常被描述为短，中，长测序。短，中测序技术依赖于DNA片段的推断信息。长测序技术，像Irys系统，保留原始的基因组结构，它可以更深入的了解基因组变化。直接可视化的基因组装和高通量的单分子成像能力使结构变异的全面检测得以实现，能显著改善基因组组装，并最终得到单倍型。
科学副主任Kevin V. Shianna博士指出：“我们定期评估对基因组学和生物信息学有重大应用的新技术，在创新、需求和商业准备的基础上评价这些系统。”“BioNano的Irys系统提供的长片段基因组信息对于我们现有的测序技术是个极大的补充，使我们能够观察到更完整的基因组变异情况。”
Mon Jul 8, 2013 8:00am EDT
BioNano Genomics and New York Genome Center Enter Into a Strategic Collaboration
PR Newswire
SAN DIEGO and NEW YORK, July 8, 2013 /PRNewswire/ -- BioNano Genomics and the New York Genome Center (NYGC) announced today a strategic partnership between the two institutions that includes the purchase of an Irys™ System by NYGC.
"The New York Genome Center is creating one of the largest and most ambitious genomics and bioinformatics facilities in North America, and we are thrilled to have them bring our platform in-house," said Todd Dickinson, Ph.D., vice president, Global Commercial Operations. "For BioNano, demonstrating the ability to deliver a commercial-ready technology that can address the long-range information needs of a premier genome center like NYGC marks an important milestone. With their Irys System, the NYGC will now provide their direct research community with the most advanced long-read commercial technology to accelerate translational research and ultimately improve human health, consistent with the mission of this new center."
NYGC was founded in 2010 to speed biomedical research and improve clinical care through a collaborative approach to genomic data and resources. In 2012, NYGC launched its Integrated Genomic Solutions, custom-built services incorporating high-throughput sequencing, bioinformatics analysis, and data management. Later this year, the independent non-profit will open its state-of-the-art facility and permanent headquarters in lower Manhattan. The facility will provide a collective workspace available to researchers to access the most advanced technologies and sequencing and bioinformatics leadership.
"Innovation and cutting-edge technologies are key to our vision of providing high quality genomics sequencing and bioinformatics services to researchers in New York City and beyond," said Robert B. Darnell, M.D., Ph.D., president and scientific director of NYGC. "Genomics researchers and clinicians need accurate, comprehensive detection of genomic structural variation and to finish genome assemblies to accurately detect and diagnose diseases and improve treatments for patients around the world."
Genomic sequencing technologies are often described as short-, medium-, or long-read. Short- and medium-read technologies rely on inferring information from short fragments of DNA. Long-read technologies, like the Irys System, preserve the native genomic structure, which provides deeper insights into genome variations. The ability to directly visualize the genome with high-throughput single molecule imaging enables the comprehensive detection of structural variation, significantly improved genome assemblies, and ultimately haplotype phasing.
"At NYGC, we regularly assess new technologies that have significant applications for genomics and bioinformatics and evaluate these systems based on innovation, need, and commercial readiness," said Kevin V. Shianna, Ph.D., Deputy Scientific Director, Sequencing. "The long-range genomic information from BioNano's Irys System is highly complementary to our existing sequencing technologies and allows us to achieve a significantly more complete view of the genome and its variation."
About the New York Genome Center
Founded in August 2010, the New York Genome Center (NYGC) is an independent, non-profit organization that leverages the collaborative resources of leading academic medical centers, research universities, and commercial organizations. Our vision is to transform medical research and clinical care in New York and beyond through the creation of one of the largest genomics research facilities in North America, while integrating sequencing, bioinformatics, data management, and cutting-edge genomics research. For more information, visit www.nygenome.org.
About Irys
Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays™ where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long "reads" ranging from hundreds of kilobases to a megabase, where the sample's valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.
About BioNano Genomics
Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company's platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.
Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
SOURCE BioNano Genomics